Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high- and low-dose rivaroxaban with aspirin by Boonyawat, K. et al.






The following full text is a publisher's version.
 
 





Please be advised that this information was generated on 2021-11-02 and may be subject to
change.
308  |    Res Pract Thromb Haemost. 2021;5:308–313.wileyonlinelibrary.com/journal/rth2
Received: 2 September 2020  | Revised: 2 November 2020  | Accepted: 9 November 2020
DOI: 10.1002/rth2.12474  
O R I G I N A L  A R T I C L E
Heavy menstrual bleeding in women on anticoagulant 
treatment for venous thromboembolism: Comparison of high- 
and low- dose rivaroxaban with aspirin
Kochawan Boonyawat MD, MSc1 |   Anthonie W. A. Lensing MD, PhD2 |    
Martin H. Prins MD, PhD3 |   Jan Beyer- Westendorf MD4,5 |   Paolo Prandoni MD, PhD6 |   
Ida Martinelli MD, PhD7  |   Saskia Middeldorp MD, PhD8  |   Akos F. Pap MSc2 |    
Jeffrey I. Weitz MD9,10 |   Mark Crowther MD, MSc10
1Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
2Bayer Healthcare, Wuppertal, Germany
3Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Center, Maastricht, The Netherlands
4Department of Medicine I, Division of Hematology and Hemostaseology, University Hospital "Carl Gustav Carus" Dresden, Dresden, Germany
5King's Thrombosis Service, Department of Hematology, King’s College London, London, UK
6Arianna Foundation on Anticoagulation, Bologna, Italy
7Fondazione IRCCS Ca' Granda- Ospedale Maggiore Policlinico, A. Bianchi Bonomi Hemophilia and Thrombosis Center, Milano, Italy
8Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
9Thrombosis & Atherosclerosis Research Institute and McMaster University, Hamilton, ON, Canada
10Department of Medicine, McMaster University, Hamilton, ON, Canada
This is an open access article under the terms of the Creative Commons Attribution- NonCommercial- NoDerivs License, which permits use and distribution in 
any medium, provided the original work is properly cited, the use is non- commercial and no modifications or adaptations are made.
© 2021 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis 
and Haemostasis (ISTH).
Correspondence
Kochawan Boonyawat, Department 
of Medicine, Ramathibodi Hospital, 
Mahidol University, 270 Rama 6th Road, 
Rachathewi, Bangkok, 10400, Thailand.
Email: kochawan.boo@mahidol.ac.th
Funding information
Bayer; Janssen Research and 
Development
Handling Editor: Dr Mary Cushman.
Abstract
Background: Rivaroxaban may induce heavy menstrual bleeding. It is unknown if this 
effect is dose related or if rivaroxaban is associated with more menstrual bleeding 
than aspirin.
Objectives: To demonstrate and compare menstrual patterns and actions taken 
among women receiving aspirin and two doses of rivaroxaban.
Methods: The EINSTEIN- CHOICE trial compared once- daily rivaroxaban 20 mg, ri-
varoxaban 10 mg, and aspirin 100 mg for extended treatment of venous thrombo-
embolism in patients who had completed 6 to 12 months of anticoagulant therapy. In 
362 women with menstrual cycles, menstrual flow duration and intensity assessed at 
days 30, 90, 180, and 360 were compared with those before starting anticoagulant 
therapy.
Results: Menstrual flow duration increased in 12%- 18% of the 134 women given 
20- mg rivaroxaban, in 6% to 12% of 120 women given 10- mg rivaroxaban, and in 
9% to 12% of 108 women given aspirin. Corresponding increases in flow intensity 
were 19% to 24%, 14% to 21%, and 13% to 20%. The odds ratios (ORs) for increased 
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Essentials
• It is unknown if rivaroxaban associated heavy menstrual bleeding (HMB) is dose related.
• Menstrual bleeding patterns and actions taken were collected in this substudy of the EINSTEIN CHOICE trial.
• Rivaroxaban 20 mg may increase menstrual bleeding compared with the lower dose or aspirin.
• Rivaroxaban 10 mg is reasonable for the extended treatment in women who are experiencing HMB.
1  |  INTRODUC TION
Heavy menstrual bleeding (HMB) has been defined as excessive 
menstrual blood loss that interferes with the woman’s physical, emo-
tional, social, and material quality of life, which can occur alone or in 
combination with other symptoms.1 HMB is a common complaint in 
women receiving oral anticoagulants including vitamin K antagonists 
and direct oral factor Xa inhibitors2,3, whereas no such signal was 
observed with dabigatran.4 Rivaroxaban is associated with increased 
and/or prolonged menstrual bleeding in up to 30% of women re-
ceiving therapeutic doses (20 mg) for the treatment of venous 
thromboembolism.5- 7 Post hoc analysis of the pooled EINSTEIN- DVT 
and EINSTEIN- PE trials showed a higher rate of HMB in rivaroxaban- 
treated women compared with those treated with enoxaparin over-
lapped and followed by a vitamin K antagonist.8 HMB leading to 
transfusion of red blood cells mainly occurred in women with anemia 
(hemoglobin < 12 g/L) or gynecological disorders, such as uterine 
fibroids and/or adenomyosis at randomization. Also, in these open- 
label studies, rivaroxaban- treated women more frequently needed a 
medical or surgical intervention to reduce abnormal uterine bleeding 
than those treated with a vitamin K antagonist.9
Although HMB associated with rivaroxaban is rarely life threat-
ening, it may have a negative impact on the quality of life, especially 
in women requiring extended anticoagulant therapy. Temporary 
interruption of rivaroxaban during menses or use of reduced 
doses has been used to manage HMB.5,6,10 However, both strate-
gies may be associated with an increased risk of recurrent venous 
thromboembolism.
EINSTEIN- CHOICE compared once- daily rivaroxaban 20 mg, 
rivaroxaban 10 mg, or aspirin 100 mg for extended treatment in 
menstrual flow duration were 1.36 (95% confidence interval [CI], 0.62- 2.96) for rivar-
oxaban 20 mg versus aspirin, 0.77 (95% CI, 0.33- 1.81) for rivaroxaban 10 mg versus 
aspirin, and 0.57 (95% CI, 0.26- 1.25) for rivaroxaban 10 mg versus 20 mg. The ORs for 
increased menstrual flow intensity were 1.41 (95% CI, 0.67- 2.99), 1.07 (95% CI, 0.49- 
2.34), and 0.76 (95% CI, 0.37- 1.57), respectively.
Conclusions: There were no statistically significant differences in menstrual hemor-
rhage patterns between women treated with 10 or 20 mg of rivaroxaban and aspirin. 
Compared with 10- mg rivaroxaban or aspirin, 20- mg rivaroxaban showed numerically 
more often increased menstrual flow duration and intensity.
K E Y W O R D S
anticoagulants, aspirin, heavy menstrual bleeding, rivaroxaban, venous thromboembolism
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patients who had completed 6 to 12 months of anticoagulation for 
their index event. Compared with aspirin, both doses of rivaroxaban 
reduced the risk of recurrence by about 70% without significantly 
increasing the risk of major bleeding.11 As part of the study, we pro-
spectively collected data on the duration and intensity of menstrual 
bleeding as well as the actions taken to manage it.
2  |  METHODS
2.1  |  Patients
For this substudy, we prospectively collected data on the duration and 
intensity of menstrual bleeding from women enrolled in the EINSTEIN- 
CHOICE trial who reported having menstrual cycles. In brief, 
EINSTEIN- CHOICE was a 3- arm, parallel- group, multicenter, double- 
blind, and double- dummy randomized trial. Patients were eligible for 
inclusion in the study if they were ≥18 years of age; had objectively 
confirmed, symptomatic proximal deep vein thrombosis or pulmonary 
embolism; had been treated for 6 to 12 months with an anticoagulant, 
either a vitamin K antagonist or direct oral anticoagulants such as da-
bigatran, rivaroxaban, apixaban, or edoxaban; and had not interrupted 
therapy for more than 7 days before randomization. Patients were 
ineligible if they had a contraindication to continued anticoagulant 
therapy or if they required extended therapy with anticoagulants at 
therapeutic doses or antiplatelet therapy. Additional ineligibility crite-
ria included a calculated creatinine clearance of <30 mL/min or hepatic 
disease associated with a coagulopathy. Participants were randomly 
assigned to receive once- daily rivaroxaban 20 mg, rivaroxaban 10 mg, 
or aspirin 100 mg for up to 1 year. The protocol was approved by the 
institutional review board at each participating center, and signed in-
formed consent was obtained from all the patients.
2.2  |  Assessment of duration and intensity of 
menstrual bleeding
Standardized data entry forms were developed to document the 
duration and intensity of menstrual bleeding. During follow- up vis-








Age, y, median (IQR) 38 (32- 44) 38 (30- 46) 39 (32- 45)
Weight, n (%)
≤70 kg 64 (47.8) 54 (45.0) 57 (52.8)
70 to ≤90 kg 36 (26.9) 32 (26.7) 26 (24.1)
>90 kg 34 (25.4) 34 (28.3) 25 (23.1)
Body mass index, n (%)
<30 kg/m2 87 (64.9) 78 (65.0) 75 (69.4)
≥30 kg/m2 47 (35.1) 42 (35.0) 33 (30.6)
Creatinine clearance, n (%)
<50 mL/min
50 to <80 mL/min 11 (8.2) 7 (5.8) 5 (4.6)
≥80 mL/min 123 (91.8) 113 (94.2) 103 (95.4)
Prior anticoagulation, n (%)
DOACs 53 (39.5) 51 (42.5) 52 (48.1)
Heparin/VKA 69 (50.7) 57 (47.5) 48 (44.4)
Combinations DOACs/
heparin/VKA
12 (9.0) 12 (10.0) 8 (7.4)
Hemoglobin, g/dL, median 
(IQR)
13.3 (12.4- 14.2) 13.1 (12.4- 13.8) 13.3 (12.4- 13.9)
Hemoglobin < 12 g/dL, n (%) 27 (20.1) 23 (19.2) 22 (20.4)
Iron supplementation, n (%) 7 (5.2) 12 (10.0) 5 (4.6)
NSAID use, n (%) 0 1 (8.3) 0
History of heavy menstrual 
bleeding, n (%)
2 (1.5) 3 (2.5) 0
Gynecological disorders, 
n (%)
3 (2.2) 5 (4.2) 7 (6.5)
Abbreviations: DOACs, direct oral anticoagulants; IQR, interquartile range; NSAID, nonsteroidal 
anti- inflammatory drug; VKA, vitamin K antagonist.
TA B L E  1  Demographic and clinical 
characteristics at baseline
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menstrual cycles at baseline were asked to compare menstrual flow 
duration and intensity of their last menstruation with their men-
struation before the start of any anticoagulant therapy. Change in 
menstrual flow duration was reported as shorter than usual, as usual, 
or longer than usual, and change in menstrual intensity was reported 
as less than usual, as usual, or more than usual. Actions taken to 
manage menstrual bleeding were recorded, including interruption or 
stop of study medication, changes in contraceptive therapy, blood 
transfusion, use of prohemostatic or antifibrinolytic drugs, use of 
other concomitant medications, or referral to a gynecologist.
2.3  |  Statistical analysis
Baseline characteristics and outcomes for each group were summa-
rized using descriptive statistics. Data on menstrual flow duration and 
intensity were considered during the study treatment period, but only 
from the time of administration of the first dose of study medication to 
48 hours after the administration of the last dose. Because the clinical 
question of interest is longer or more intense menstruation, general lin-
ear mixed modeling with binary distribution and logit link function was 
applied, calculating odds ratios (ORs) for longer or more intense versus 
other responses. Calculations were performed separately for duration 
and intensity of menstrual bleeding, allowing for within- subject cor-
relation and missing data, by including random effect, and adjusted for 
the presence of a history of HMB; 95% confidence intervals (CIs) and P 
values were adjusted for multiple comparisons.
3  |  RESULTS
From March 2014 to March 2016, 1500 women were enrolled in the 
EINSTEIN- CHOICE trial, of whom 377 (25.1%) reported having men-
strual cycles. Data on menstrual flow duration and intensity were 
collected from 362 women (96.0%), of whom 134 (37.0%) received 
rivaroxaban 20 mg, 120 (33.1%) received rivaroxaban 10 mg, and 
108 (29.8%) received aspirin. Iron supplementation at baseline was 
reported in 7 (5.2%), 12 (10.0%), and 5 (4.6%) women in the rivar-
oxaban 20 mg, rivaroxaban 10 mg, and aspirin groups, respectively, 
whereas a history of HMB was reported in 2 (1.5%), 3 (2.5%), and 0 
women, respectively. Other baseline characteristics are presented 
in Table 1.
3.1  |  Duration and intensity of menstrual bleeding
The observed frequencies of shorter/less than usual, as usual, and 
longer/more than usual duration/intensity of menstruation are pro-
vided in Tables 2 and 3. Over the 5 follow- up visits, in women ran-
domly assigned to rivaroxaban 20 mg, rivaroxaban 10 mg, or aspirin, 
the frequency of a menstrual flow duration of longer than usual ranged 
from 12% to 18%, 6% to 12%, and 9% to 12%, respectively, whereas 
the frequency of a menstrual flow intensity of more than usual ranged 
from 19% to 24%, 14% to 21%, and 13% to 20%, respectively.
3.2  |  Comparisons among treatment groups
Rivaroxaban 20 mg versus aspirin. The frequency of increased men-
strual flow duration and intensity was numerically (but not statisti-
cally significantly) higher in the rivaroxaban 20- mg group compared 
with the aspirin group (OR, 1.36; 95% CI, 0.62- 2.96; P = .63; and OR, 
1.41; 95% CI, 0.67- 2.99; P = .52, respectively).
Rivaroxaban 10 mg versus aspirin. The frequency of increased 
menstrual flow duration (OR, 0.77; 95% CI, 0.33- 1.81; P = .76) and 
intensity (OR, 1.07; 95% CI, 0.49- 2.34; P = .98) were numerically (but 
not statistically significantly) lower in the rivaroxaban 10- mg group 
compared with the aspirin group.
Rivaroxaban 10 mg versus rivaroxaban 20 mg. The frequency of in-
creased menstrual flow duration and intensity was numerically (but not 
statistically significantly) lower (OR, 0.57; 95% CI, 0.26- 1.25; P = .21; 
and OR, 0.76; 95% CI, 0.37- 1.57; P = .64, respectively) in the rivarox-
aban 10- mg group compared with the rivaroxaban 20- mg group.
3.3  |  Actions taken to manage HMB
The types of actions taken for the management of HMB are pre-
sented in Table 4. Overall, 21 (15.7%), 15 (12.5%), and 15 (13.9%) 
women in the rivaroxaban 20- mg, rivaroxaban 10- mg, and aspirin 



















than usual As usual
Longer 
than usual
Day 30 7 (5.6) 94 (75.8) 16 (12.9) 5 (4.6) 87 (80.6) 6 (5.6) 8 (8.2) 74 (76.3) 12 (12.4)
Day 90 4 (3.4) 93 (78.8) 14 (11.9) 4 (4.0) 78 (77.2) 12 (11.9) 12 (13.0) 67 (72.8) 11 (12.0)
Day 180 8 (7.1) 87 (77.0) 14 (12.4) 9 (9.3) 76 (78.4) 8 (8.2) 9 (10.6) 65 (76.5) 8 (9.4)
Day 270 6 (7.6) 56 (70.9) 14 (17.7) 4 (5.7) 58 (82.9) 6 (8.6) 8 (12.3) 50 (76.9) 6 (9.2)
Day 360 4 (5.0) 59 (73.8) 14 (17.5) 4 (5.9) 59 (86.8) 4 (5.9) 6 (9.2) 49 (75.4) 8 (12.3)
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groups, respectively, had an action taken. Stopping or interruption 
of study medication, use of blood transfusion, and use of prohemo-
static/antifibrinolytic therapy were reported 9 times in the rivaroxa-
ban 20- mg group compared with 2 times in the other two treatment 
groups. However, there were no statistical differences between 
groups.
4  |  DISCUSSION
The results of this substudy of the EINSTEIN- CHOICE trial found 
that flow duration and intensity of menstrual bleeding, as well 
as actions taken to manage HMB, increased nonsignificantly in 
women treated with rivaroxaban 20 mg compared with either 
rivaroxaban 10 mg or aspirin. The comparison of rivaroxaban 
10 mg with aspirin showed a small decrease in flow duration but 
an equally small increase in flow intensity with rivaroxaban, while 
the number of actions taken to manage HMB was comparable and 
approximates 15%. The EINSTEIN- CHOICE trial demonstrated 
that rivaroxaban 10 mg once daily had comparable efficacy in the 
prevention of recurrent venous thromboembolism compared with 
rivaroxaban 20 mg once daily and that the 10- mg dose appeared 
to be safer with regard to increased menstrual bleeding.11 Hence, 
our findings suggest that in treating women with HMB, reducing 
the dose of rivaroxaban to 10 mg daily after 6 months of treatment 
is reasonable.10
Our study has several strengths. The current analysis was pro-
spectively planned as a substudy of the double- blind EINSTEIN- 
CHOICE trial and included >100 women per treatment arm. 
Follow- up data were missing in only 15 (4.0%) of the 377 women 
who reported menstrual cycles at baseline. The proportions of miss-
ing data were relatively small and comparable for the three study 
arms (Table 2 and 3). Furthermore, missing data were taken into ac-
count in our statistical strategies. The strength of our conclusions is 
increased by the double- blind, randomized study design that mini-
mizes the risk of confounding by indication.
For the limitations, since all women had been treated before 
the start of the study with therapeutic doses of anticoagulants 
for 6 to 12 months, the comparison of menstrual cycles during 
the study with cycles from before the start of any anticoagula-
tion might not be fully accurate, but this imprecise recall applies 
equally to all patients in the three treatment groups. Women 
who had (severe) HMB in the months after the start of their ini-
tial anticoagulation might have had already actions taken before 
























Day 30 9 (7.3) 78 (62.9) 30 (24.2) 5 (4.6) 77 (71.3) 18 (16.7) 14 (14.4) 61 (62.9) 19 (19.6)
Day 90 6 (5.1) 78 (66.1) 27 (22.9) 6 (5.9) 68 (67.3) 21 (20.8) 15 (16.3) 60 (65.2) 15 
(16.3)
Day 180 10 (8.8) 75 (66.4) 24 (21.2) 7 (7.2) 69 (71.1) 18 (18.6) 10 (11.8) 61 (71.8) 11 
(12.9)
Day 270 7 (8.9) 54 (68.4) 15 (19.0) 4 (5.7) 54 (77.1) 10 (14.3) 9 (13.8) 43 (66.2) 12 
(18.5)









Patients with any action, n (%) 21 (15.7) 15 (12.5) 15 (13.9)
Change in hormonal therapy 9 (6.7) 9 (7.5) 8 (7.4)
Stop or interruption of study 
medication
6 (4.5) 2 (1.7) 2 (1.9)
Referral to gynecologist 4 (3.0) 4 (3.3) 4 (3.7)
Blood transfusion 2 (1.5) 0 0
Prohemostatic/antifibrinolytic 
therapy
1 (0.7)a  0 0
Iron supplementation 0 1 (0.8) 1 (0.9)
aTranexamic acid. 
TA B L E  4  New action taken for 
management of heavy or prolonged 
menstrual bleeding during study 
treatment
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enrollment in this study or may have declined extended anticoag-
ulation and thus could not participate.12 Though we have baseline 
hemoglobin levels, we did not have hemoglobin values during or 
at the end of the study. Finally, we defined actions taken to con-
trol HMB on the forehand; one might argue that stopping or inter-
rupting the study medication and blood transfusion are clinically 
more important actions. Therefore, the inclusion of “change of 
hormonal therapy” and “referral to a gynecologist” might have re-
duced the difference between groups. Based on the frequency of 
stopping or interruption of therapy and blood transfusion (6% vs 
2%), approximately 700 patients would be required for the com-
parison of rivaroxaban 20 mg versus 10 mg in a two- arm study.
In conclusion, there were no statistically significant differences 
in menstrual bleeding patterns between 10 or 20 mg of rivaroxaban 
and aspirin. Compared with 10- mg rivaroxaban or aspirin, 20- mg ri-
varoxaban showed numerically more often increased menstrual flow 
duration and intensity, whereas, compared with aspirin, there was less 
often increased flow duration, but more often increased flow inten-
sity with 10- mg rivaroxaban. Our findings support the use of a 10- mg 
once- daily dose of rivaroxaban for the secondary prevention of venous 
thrombosis in appropriate women who are experiencing menses.
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